

COMPANY OVERVIEW

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.

RECENT NEWS

Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board

Jan 17 2019, 7:30 AM EST

Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland

Jan 9 2019, 7:30 AM EST

Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate

Jan 3 2019, 7:30 AM EST

STOCK OVERVIEW

| | |
|---------------|------------------|
| Symbol | MBRX |
| Exchange | Nasdaq |
| Market Cap | 40.51m |
| Last Price | \$1.42 |
| 52-Week Range | \$0.934 - \$3.34 |

01/18/2019 04:00 PM EST

INVESTOR RELATIONS

Lytham Partners, LLC
Joe Dorame
Managing Partner
T: (602) 889-9700

MANAGEMENT TEAM

Walter V. Klemp

Founder, President, Chairman, CEO, and
Business Advisory Board Member

Donald Picker, PhD

Chief Scientific Officer

Robert Shepard, MD, FACP

Chief Medical Officer - Hematology

Sandra Silberman, MD, PhD

Chief Medical Officer - New Products

Jonathan P. Foster

Chief Financial Officer

MOLECULIN BIOTECH, INC.

5300 Memorial Drive
Suite 950
Houston, TX 77007
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.